vs
Inogen Inc（INGN）与Sanara MedTech Inc.（SMTI）财务数据对比。点击上方公司名可切换其他公司
Inogen Inc的季度营收约是Sanara MedTech Inc.的2.5倍（$68.6M vs $27.5M）。Sanara MedTech Inc.同比增速更快（4.6% vs 3.4%）。Sanara MedTech Inc.自由现金流更多（$3.9M vs $-1.9M）。过去两年Sanara MedTech Inc.的营收复合增速更高（21.8% vs 4.2%）
Inogen Inc是一家专注于呼吸医疗设备领域的医疗科技企业，主要研发、生产和销售便携式制氧机及配套呼吸护理产品，面向北美、欧洲等地区需要长期氧疗的慢性呼吸系统疾病患者，服务居家及出行场景，提升用户生活质量。
Sanara MedTech Inc.是一家总部位于美国的医疗科技企业，专注于研发、生产和销售外科手术、伤口护理、康复期护理类创新医疗产品，主要服务北美地区的医院、医疗机构及长期护理场所，旗下多款产品获FDA认证，旨在提升患者护理效果并降低医疗运营成本。
INGN vs SMTI — 直观对比
营收规模更大
INGN
是对方的2.5倍
$27.5M
营收增速更快
SMTI
高出1.2%
3.4%
自由现金流更多
SMTI
多$5.8M
$-1.9M
两年增速更快
SMTI
近两年复合增速
4.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $68.6M | $27.5M |
| 净利润 | — | $-1.6M |
| 毛利率 | 51.4% | 93.2% |
| 营业利润率 | -13.6% | 23.5% |
| 净利率 | — | -5.9% |
| 营收同比 | 3.4% | 4.6% |
| 净利润同比 | — | 5.3% |
| 每股收益（稀释后） | $-0.26 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INGNSMTI
| Q4 25 | $68.6M | $27.5M | ||
| Q3 25 | $79.1M | $26.3M | ||
| Q2 25 | $79.2M | $25.8M | ||
| Q1 25 | $68.5M | $23.4M | ||
| Q4 24 | $66.3M | $26.3M | ||
| Q3 24 | $74.9M | $21.7M | ||
| Q2 24 | $74.4M | $20.2M | ||
| Q1 24 | $63.1M | $18.5M |
净利润INGNSMTI
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-5.3M | $-30.4M | ||
| Q2 25 | $-4.2M | $-2.0M | ||
| Q1 25 | $-6.2M | $-3.5M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $-6.0M | $-2.9M | ||
| Q2 24 | $-5.6M | $-3.5M | ||
| Q1 24 | $-14.6M | $-1.8M |
毛利率INGNSMTI
| Q4 25 | 51.4% | 93.2% | ||
| Q3 25 | 52.2% | 92.9% | ||
| Q2 25 | 52.2% | 92.5% | ||
| Q1 25 | 53.1% | 92.2% | ||
| Q4 24 | 54.7% | 91.4% | ||
| Q3 24 | 55.2% | 90.8% | ||
| Q2 24 | 57.4% | 90.0% | ||
| Q1 24 | 54.5% | 89.8% |
营业利润率INGNSMTI
| Q4 25 | -13.6% | 23.5% | ||
| Q3 25 | -9.0% | 11.2% | ||
| Q2 25 | -7.7% | -0.1% | ||
| Q1 25 | -11.2% | -8.9% | ||
| Q4 24 | -17.2% | 18.6% | ||
| Q3 24 | -10.4% | 3.6% | ||
| Q2 24 | -9.5% | -14.3% | ||
| Q1 24 | -25.8% | -8.3% |
净利率INGNSMTI
| Q4 25 | — | -5.9% | ||
| Q3 25 | -6.7% | -115.5% | ||
| Q2 25 | -5.2% | -7.8% | ||
| Q1 25 | -9.0% | -15.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | -8.0% | -13.2% | ||
| Q2 24 | -7.5% | -17.4% | ||
| Q1 24 | -23.1% | -9.5% |
每股收益（稀释后）INGNSMTI
| Q4 25 | $-0.26 | $-0.32 | ||
| Q3 25 | $-0.20 | $-3.40 | ||
| Q2 25 | $-0.15 | $-0.23 | ||
| Q1 25 | $-0.25 | $-0.41 | ||
| Q4 24 | $-0.41 | $-0.18 | ||
| Q3 24 | $-0.25 | $-0.34 | ||
| Q2 24 | $-0.24 | $-0.41 | ||
| Q1 24 | $-0.62 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.7M | $16.6M |
| 总债务越低越好 | — | $46.0M |
| 股东权益账面价值 | $192.2M | $5.9M |
| 总资产 | $298.6M | $72.9M |
| 负债/权益比越低杠杆越低 | — | 7.74× |
8季度趋势，按日历期对齐
现金及短期投资INGNSMTI
| Q4 25 | $103.7M | $16.6M | ||
| Q3 25 | $106.5M | $14.9M | ||
| Q2 25 | $103.7M | $17.0M | ||
| Q1 25 | $118.9M | $20.7M | ||
| Q4 24 | $113.8M | $15.9M | ||
| Q3 24 | $105.7M | $16.3M | ||
| Q2 24 | $97.9M | $6.2M | ||
| Q1 24 | $107.4M | $2.8M |
总债务INGNSMTI
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
股东权益INGNSMTI
| Q4 25 | $192.2M | $5.9M | ||
| Q3 25 | $197.2M | $6.1M | ||
| Q2 25 | $199.5M | $35.4M | ||
| Q1 25 | $198.0M | $36.7M | ||
| Q4 24 | $173.9M | $39.4M | ||
| Q3 24 | $185.4M | $39.8M | ||
| Q2 24 | $187.6M | $41.7M | ||
| Q1 24 | $191.9M | $43.3M |
总资产INGNSMTI
| Q4 25 | $298.6M | $72.9M | ||
| Q3 25 | $307.0M | $71.1M | ||
| Q2 25 | $312.0M | $98.8M | ||
| Q1 25 | $308.4M | $96.4M | ||
| Q4 24 | $296.2M | $88.1M | ||
| Q3 24 | $306.2M | $88.5M | ||
| Q2 24 | $308.9M | $73.4M | ||
| Q1 24 | $315.6M | $70.9M |
负债/权益比INGNSMTI
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-943.0K | $3.9M |
| 自由现金流经营现金流 - 资本支出 | $-1.9M | $3.9M |
| 自由现金流率自由现金流/营收 | -2.8% | 14.0% |
| 资本支出强度资本支出/营收 | 1.4% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.7M | $2.2M |
8季度趋势，按日历期对齐
经营现金流INGNSMTI
| Q4 25 | $-943.0K | $3.9M | ||
| Q3 25 | $2.2M | $2.2M | ||
| Q2 25 | $4.3M | $2.7M | ||
| Q1 25 | $-16.8M | $-2.0M | ||
| Q4 24 | $-3.0M | $932.0K | ||
| Q3 24 | $7.0M | $2.1M | ||
| Q2 24 | $6.7M | $-1.4M | ||
| Q1 24 | $-4.7M | $-1.6M |
自由现金流INGNSMTI
| Q4 25 | $-1.9M | $3.9M | ||
| Q3 25 | $1.6M | $1.1M | ||
| Q2 25 | $3.7M | $902.7K | ||
| Q1 25 | $-17.1M | $-3.7M | ||
| Q4 24 | $-3.3M | $859.9K | ||
| Q3 24 | $5.3M | $2.0M | ||
| Q2 24 | $6.6M | $-1.5M | ||
| Q1 24 | $-6.1M | $-1.7M |
自由现金流率INGNSMTI
| Q4 25 | -2.8% | 14.0% | ||
| Q3 25 | 2.0% | 4.2% | ||
| Q2 25 | 4.6% | 3.5% | ||
| Q1 25 | -24.9% | -15.9% | ||
| Q4 24 | -5.0% | 3.3% | ||
| Q3 24 | 7.1% | 9.4% | ||
| Q2 24 | 8.9% | -7.3% | ||
| Q1 24 | -9.6% | -9.0% |
资本支出强度INGNSMTI
| Q4 25 | 1.4% | 0.3% | ||
| Q3 25 | 0.7% | 4.0% | ||
| Q2 25 | 0.9% | 6.8% | ||
| Q1 25 | 0.4% | 7.4% | ||
| Q4 24 | 0.5% | 0.3% | ||
| Q3 24 | 2.2% | 0.0% | ||
| Q2 24 | 0.1% | 0.3% | ||
| Q1 24 | 2.1% | 0.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INGN
暂无分部数据
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
